secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2026-07-06T20:11:47+00:00
Accession:  0001193125-26-296190
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris Therapeutics announces director resignation and election of Laurie Keating
--------------------------------------------------------------------------------

- Morana Jovan-Embiricos resigned from board and audit committee effective July 3, 2026; no disagreement with company.
- Laurie Keating elected as Class I director effective August 1, 2026, and appointed to audit committee.
- Keating receives option for 18,000 shares vesting over 3 years, annual cash $40,000 board plus $7,500 audit committee.
- Keating will enter standard indemnification agreement; compensation per non-employee director policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526296190/0001193125-26-296190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526296190/d34897d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-296190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer